Akorn Inc. is recalling 16,216 cartons of Myorisan (isotretinoin capsules, USP), 40 mg, because of a labeling error on the outer packaging. While the individual prescription packs inside are correctly labeled, the secondary outer carton incorrectly states the dosage is 40 mg instead of 30 mg. This recall affects Myorisan distributed nationwide in the United States.
A labeling mix-up regarding the dosage strength can lead to confusion for patients or healthcare providers, potentially resulting in the administration of an incorrect dose of medication.
Contact healthcare provider or pharmacist and return for refund.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.